AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37939133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nivolumab followed by maximal safe resection and an intracerebral injection of ipilimumab alone or combined with nivolumab, biweekly adjuvant nivolumab up to five times.
Number of subjects: 24
Study 37939141 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF; 50/200/25 mg)
Number of subjects: 33
Study 37939147 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG
Number of subjects: 258
Study 37939147 — intervention group
Group type: COMPARATOR
Intervention: non-ICG
Number of subjects: 258
Study 37939259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral toll-like receptor 9 (TLR9) agonist with local low-dose radiation and ibrutinib
Number of subjects: 0
Study 37939264 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormonal contraceptives (CHCs) cessation
Number of subjects: 66
Study 37939264 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without CHC)
Number of subjects: 66
Study 37939262 — intervention group
Group type: EXPERIMENTAL
Intervention: 5F11-Ts (anti-CD30 CAR T cells)
Number of subjects: 21
Study 37939328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-randomized workplace intervention
Number of subjects: 0
Study 37939328 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37939397 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled breath condensate (EBC) from patients with confirmed PE
Number of subjects: 77
Study 37939397 — intervention group
Group type: COMPARATOR
Intervention: Exhaled breath condensate (EBC) from controls
Number of subjects: 77
Study 37939520 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant massage training
Number of subjects: 60
Study 37939628 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA-guided interventions in addition to oncological standard care
Number of subjects: 181
Study 37939628 — intervention group
Group type: COMPARATOR
Intervention: Oncological care alone
Number of subjects: 181
Study 37940142 — intervention group
Group type: EXPERIMENTAL
Intervention: Live zoster vaccine
Number of subjects: 1505647
Study 37940151 — intervention group
Group type: EXPERIMENTAL
Intervention: uCaP microRNA biomarker model (miR-222-3p, miR-24-3p, miR-30c-5p)
Number of subjects: 0
Study 37940161 — intervention group
Group type: EXPERIMENTAL
Intervention: PREPARED strategy
Number of subjects: 840
Study 37940161 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 840
Study 37940349 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of the excursion of the ZOA using a linear probe
Number of subjects: 75
Study 37940349 — intervention group
Group type: COMPARATOR
Intervention: Assessment of the excursion of the DOD using a curvilinear probe
Number of subjects: 75
Study 37940349 — intervention group
Group type: COMPARATOR
Intervention: Assessment of the thickening fraction of the ZOA
Number of subjects: 75
Study 37940357 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (7-day course)
Number of subjects: 50
Study 37940357 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study 37940377 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation (PPV)
Number of subjects: 4876
Study 37940377 — intervention group
Group type: COMPARATOR
Intervention: No PPV
Number of subjects: 4876
Study 37940377 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 4876
Study 37940383 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegunigalsidase alfa
Number of subjects: 77
Study 37940383 — intervention group
Group type: COMPARATOR
Intervention: Agalsidase beta
Number of subjects: 77
Study 37940387 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroform Atlas Stent System (used for treatment of proximal ICA aneurysms)
Number of subjects: 182
Study 37940387 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroform Atlas Stent System (used for treatment of distal anterior circulation aneurysms)
Number of subjects: 182
Study 37940433 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended antibiotic therapy (10 days of broad-spectrum antibiotics: piperacillin/tazobactam converted to amoxicillin/clavulanic acid at discharge)
Number of subjects: 87
Study 37940433 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended antibiotic therapy
Number of subjects: 87
Study 37940433 — intervention group
Group type: COMPARATOR
Intervention: Standard perioperative antibiotics (single dose before incision)
Number of subjects: 87
Study 37940433 — intervention group
Group type: COMPARATOR
Intervention: Standard perioperative antibiotics
Number of subjects: 87
Study 37940446 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks plus enzalutamide 160 mg orally once daily
Number of subjects: 102
Study 37940671 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% RNAi-based amylose-only barley flour (AmOn) and 50% wheat flour
Number of subjects: 20
Study 37940671 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% hulless barley and 50% wheat flour
Number of subjects: 20
Study 37940671 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% hulless barley and 25% wheat flour
Number of subjects: 20
Study 37940671 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% RNAi-based amylose-only barley flour (AmOn)
Number of subjects: 20
Study 37940671 — intervention group
Group type: EXPERIMENTAL
Intervention: All barley breads
Number of subjects: 20
Study 37940915 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance in Recovery Colleges (RCs)
Number of subjects: 0
Study 37940915 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-creation with RC students
Number of subjects: 0
Study 37940936 — intervention group
Group type: EXPERIMENTAL
Intervention: Treviamet® & Treviamet XR® (Sitagliptin with Metformin)
Number of subjects: 188
Study 37941012 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic arrhythmia radioablation (STAR) with dose escalation from 27.0 Gy to a maximum of 35.1 Gy while keeping the planning target volume (PTV) dose constant at 25 Gy.
Number of subjects: 15
Study 37941012 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic arrhythmia radioablation (STAR) with dose escalation.
Number of subjects: 15
Study 37941050 — intervention group
Group type: EXPERIMENTAL
Intervention: H-GAP
Number of subjects: 20
Study 37941050 — intervention group
Group type: COMPARATOR
Intervention: H-Health
Number of subjects: 20
Study 37941050 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants
Number of subjects: 20
Study 37941050 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome
Number of subjects: 20
Study 37941073 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal fluid management (high volume)
Number of subjects: 50
Study 37941073 — intervention group
Group type: COMPARATOR
Intervention: Restricted fluid management (low volume)
Number of subjects: 50
Study 37941087 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-social partnership programme (4 Zoom sessions and 4 telephone calls)
Number of subjects: 100
Study 37941087 — intervention group
Group type: COMPARATOR
Intervention: Monthly social telephone call from a trained research assistant
Number of subjects: 100
Study 37941113 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab (humanized monoclonal antibody that neutralizes interleukin-6)
Number of subjects: 0
Study 37941113 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 37941409 — intervention group
Group type: EXPERIMENTAL
Intervention: alloTSCT
Number of subjects: 217
Study 37941409 — intervention group
Group type: COMPARATOR
Intervention: autoTSCT
Number of subjects: 217
Study 37941470 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI) 80 u twice weekly for 6 months
Number of subjects: 19
Study 37941561 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy (NAST)
Number of subjects: 163
Study 37941759 — intervention group
Group type: EXPERIMENTAL
Intervention: Hula intervention, 6 months, twice per week, 60 minutes each session, plus 60 minutes of home practice per week.
Number of subjects: 0
Study 37941759 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group, no immediate intervention.
Number of subjects: 0
Study 37941823 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 avocados/family/week
Number of subjects: 72
Study 37941823 — intervention group
Group type: COMPARATOR
Intervention: 3 avocados/family/week
Number of subjects: 72
Study 37941845 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-drug-coated balloon (DCB) after bare-metal stent (BMS) implantation
Number of subjects: 223
Study 37941845 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS) only
Number of subjects: 223
Study 37941845 — intervention group
Group type: EXPERIMENTAL
Intervention: DCB-combined strategy
Number of subjects: 223
Study 37941845 — intervention group
Group type: COMPARATOR
Intervention: BMS
Number of subjects: 223
Study 37941848 — intervention group
Group type: EXPERIMENTAL
Intervention: Garmin Vivosmart 4 watch
Number of subjects: 18
Study 37941848 — intervention group
Group type: COMPARATOR
Intervention: Garmin HRM-DUAL™ chest-worn HR monitors
Number of subjects: 18
Study 37941888 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Functional Mobilization (EFM) group - loading allowed immediately after surgery
Number of subjects: 86
Study 37941888 — intervention group
Group type: COMPARATOR
Intervention: Comparison group - loading allowed at 2 weeks postoperatively
Number of subjects: 86
Study 37941979 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (79% before 2018, 52% after 2018)
Number of subjects: 336
Study 37941979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (31% after 2018)
Number of subjects: 336
Study 37941979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab and nivolumab combination (10% after 2018)
Number of subjects: 336
Study 37941979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (23%)
Number of subjects: 336
Study 37941979 — intervention group
Group type: EXPERIMENTAL
Intervention: IMDC risk category
Number of subjects: 336
Study 37941979 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line medical treatment
Number of subjects: 336
Study 37941979 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital inpatient days
Number of subjects: 336
Study 37942277 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg twice daily
Number of subjects: 4362
Study 37942277 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg twice daily
Number of subjects: 4362
Study 37942277 — intervention group
Group type: COMPARATOR
Intervention: TNFi (tumor necrosis factor inhibitors)
Number of subjects: 4362
Study 37942314 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of AMG 212
Number of subjects: 0
Study 37942314 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous (CIV) administration of AMG 212
Number of subjects: 0
Study 37942328 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg cadonilimab every 2 weeks plus lenvatinib (cohort A)
Number of subjects: 59
Study 37942328 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg cadonilimab every 3 weeks plus lenvatinib (cohort B)
Number of subjects: 59
Study 37942487 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual intracerebroventricular and intravitreal administration (specific dosage and duration not provided)
Number of subjects: 0
Study 37942487 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific intervention not provided)
Number of subjects: 0
Study 37942666 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-zirconium (TiZr) implants
Number of subjects: 91
Study 37942666 — intervention group
Group type: COMPARATOR
Intervention: Grade IV titanium (Ti) implants
Number of subjects: 91
Study 37942680 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 3700
Study 37942680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3700
Study 37942723 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 6000
Study 37942723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6000
Study 37942793 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban
Number of subjects: 420
Study 37942793 — intervention group
Group type: COMPARATOR
Intervention: Colchicine
Number of subjects: 420
Study 37942793 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control for anticoagulation hypothesis)
Number of subjects: 420
Study 37942793 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control for anti-inflammatory hypothesis)
Number of subjects: 420
Study 37942921 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg once daily
Number of subjects: 988
Study 37942921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 988
Study 37942921 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 988
Study 37942921 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 988
Study 37942921 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids at baseline
Number of subjects: 988
Study 37942921 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids withdrawal during maintenance
Number of subjects: 988
Study 37942930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB) treatment
Number of subjects: 35
Study 37943075 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanone-rich ingredient supplementation for 16 weeks
Number of subjects: 0
Study 37943221 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practice alert (BPA) suggesting guideline-recommended MRAs for eligible patients with a serum potassium of <5.0 mEq/L or novel potassium binders for those with a serum potassium of ≥5.0 mEq/L.
Number of subjects: 1210
Study 37943221 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1210
Study 37943221 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practice alert (BPA).
Number of subjects: 1210
Study 37943223 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 51
Study 37943223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 37943225 — intervention group
Group type: EXPERIMENTAL
Intervention: ICM-based multiparameter dynamic heart failure risk score (HFRS)
Number of subjects: 136
Study 37943225 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 136
Study 37943227 — intervention group
Group type: EXPERIMENTAL
Intervention: Noom (smartphone application)
Number of subjects: 182
Study 37943227 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 182
Study 37943291 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-triclosan graft (SynG)
Number of subjects: 547
Study 37943291 — intervention group
Group type: COMPARATOR
Intervention: Standard polyester graft (PolyG)
Number of subjects: 547
Study 37943291 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PolyG and SynG)
Number of subjects: 547
Study 37943300 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (250 mg intravenous injection)
Number of subjects: 137
Study 37943300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 37943335 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromodulation (noninvasive low-level tragus stimulation) 4 hours twice daily (n=8)
Number of subjects: 19
Study 37943335 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromodulation (noninvasive low-level tragus stimulation)
Number of subjects: 19
Study 37943335 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (n=11)
Number of subjects: 19
Study 37943350 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosorb
Number of subjects: 20
Study 37943351 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy followed by repeat local treatment (thermal ablation and/or surgical resection)
Number of subjects: 360
Study 37943351 — intervention group
Group type: COMPARATOR
Intervention: Repeat local treatment alone
Number of subjects: 360
Study 37943362 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitapivat
Number of subjects: 80
Study 37943362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 37943491 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for ≤2 years
Number of subjects: 146
Study 37943557 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer comparison and educational intervention for physicians and patients, including previsit emails comparing low-value testing rates and educational materials via email and text message.
Number of subjects: 314
Study 37943557 — intervention group
Group type: COMPARATOR
Intervention: General previsit preparation tips for control group physicians and patients.
Number of subjects: 314
Study 37943557 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer comparison and educational intervention for physicians and patients.
Number of subjects: 314
Study 37943580 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised therapy with an active rehabilitation robot
Number of subjects: 13
Study 37943580 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally supervised therapy
Number of subjects: 13
Study 37943580 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised therapy
Number of subjects: 13
Study 37943591 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exergame training program at rehabilitation centers followed by a 10-week home training program under remote supervision
Number of subjects: 180
Study 37943591 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study 37943594 — intervention group
Group type: EXPERIMENTAL
Intervention: e-cigarettes (adopters) in the iCanQuit app
Number of subjects: 1562
Study 37943594 — intervention group
Group type: EXPERIMENTAL
Intervention: e-cigarettes (adopters) in the QuitGuide app
Number of subjects: 1562
Study 37943594 — intervention group
Group type: COMPARATOR
Intervention: nonadopters in the iCanQuit app
Number of subjects: 1562
Study 37943594 — intervention group
Group type: COMPARATOR
Intervention: nonadopters in the QuitGuide app
Number of subjects: 1562
Study 37943608 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective socioeconomic status
Number of subjects: 0
Study 37943608 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective socioeconomic status
Number of subjects: 0
Study 37943674 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation integrated with ST (BASC) + varenicline
Number of subjects: 300
Study 37943674 — intervention group
Group type: COMPARATOR
Intervention: Behavioral activation integrated with ST (BASC) + placebo
Number of subjects: 300
Study 37943674 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard behavioral cessation treatment (ST) + varenicline
Number of subjects: 300
Study 37943674 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral cessation treatment (ST) + placebo
Number of subjects: 300
Study 37944025 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrorectus synthetic mesh
Number of subjects: 102
Study 37944025 — intervention group
Group type: COMPARATOR
Intervention: Biological mesh
Number of subjects: 102
Study 37944025 — intervention group
Group type: EXPERIMENTAL
Intervention: Both synthetic and biological mesh
Number of subjects: 102
Study 37944074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin (TRET; all-trans retinoic acid) with Fludarabine and Cytarabine (FLA)
Number of subjects: 27
Study 37944074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin (TRET; all-trans retinoic acid) with 5-azacitidine (AZA)
Number of subjects: 27
Study 37944123 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantasic individuals
Number of subjects: 34
Study 37944123 — intervention group
Group type: COMPARATOR
Intervention: Aphantasic individuals
Number of subjects: 34
Study 37944528 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepotinib (oral MET inhibitor)
Number of subjects: 24
Study 37944541 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib-venetoclax
Number of subjects: 211
Study 37944541 — intervention group
Group type: COMPARATOR
Intervention: chlorambucil-obinutuzumab
Number of subjects: 211
Study 37944586 — intervention group
Group type: EXPERIMENTAL
Intervention: EuCorVac-19 (ECV-19) vaccine
Number of subjects: 197
Study 37944925 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterosacral ligament suspension (USLS)
Number of subjects: 51
Study 37944925 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrospinous ligament fixation (SSLF)
Number of subjects: 51
Study 37945063 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral anterior quadratus lumborum nerve block with 60 mL ropivacaine 0.375%
Number of subjects: 22
Study 37945063 — intervention group
Group type: COMPARATOR
Intervention: Placebo with isotonic saline injections
Number of subjects: 22
Study 37945284 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib (FIL) treatment
Number of subjects: 121
Study 37945286 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg QD
Number of subjects: 6423
Study 37945286 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg QD
Number of subjects: 6423
Study 37945286 — intervention group
Group type: COMPARATOR
Intervention: adalimumab (RA and PsA)
Number of subjects: 6423
Study 37945286 — intervention group
Group type: COMPARATOR
Intervention: methotrexate (RA)
Number of subjects: 6423
Study 37945286 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib (both doses)
Number of subjects: 6423
Study 37945292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 1 g/kg/dose, given 24-36 hours apart
Number of subjects: 18
Study 37945292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 37945297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric derisomaltose (500-1000 mg infusion at least 21 days prior to surgery)
Number of subjects: 0
Study 37945297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37945297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric derisomaltose
Number of subjects: 0